


# “Promising” Compounds Analysis (March 2024)\*


Novel Compound/Indications (Promising and Watch & Wait) by MOA and Viral Family (N=38)



\*As of March 8, 2024

# Novel Clinical Antiviral Entry Inhibitors\*


Novel Compound/Indications (Promising, Watch & Wait (N=12))



\*As of March 8, 2024; Attachment, Capsid (Rhinovirus), Fusion

# Novel Clinical Antiviral Protease Inhibitors\*


Novel Compound/Indications (Promising, Watch & Wait, Archived (N=16))



\*As of March 8, 2024; Mpro (Coronavirus and Enterovirus)

# Novel Clinical Antiviral Replication Inhibitors\*

Novel Compound/Indications (Promising, Watch & Wait (N=9))



\*As of March 8, 2024; Polymerase, Endonuclease, Replicase, DENVNS4B

# Novel Clinical Antiviral Assembly-Release Inhibitors\*

Novel Compound/Indications (Promising, Watch & Wait, Archived (N=1))



\*As of March 8, 2024; Neuraminidase



Interested  
in engaging  
with us?

To improve our listing, developers are invited to submit non-confidential information on their compound candidates. In addition, we welcome all feedback through our online portal.

For more information, contact [nina@intrepidalliance.org](mailto:nina@intrepidalliance.org).

 [intrepidalliance.org](https://intrepidalliance.org)

 [linkedin.com/company/intrepid-alliance](https://linkedin.com/company/intrepid-alliance)